Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
October 29, 2020
Earnings Call Speaker Segments
Jake Elguicze
executiveHello, everybody, and thanks for joining the Teleflex Incorporated Q3 earnings conference call. The press release and the slides that go along with this call can be found on our site, www.teleflex.com. Just a note, this call is being webcast on our site, and you can access a replay by calling 855 to 859 to 2056, or if you're outside the US, 404 to 537 to 3406, with passcode 4907865. On the line with us today are Liam Kelly, Chairman, President and Chief Executive Officer, and Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that, we'll take your questions. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. We caution you that these statements are forward-looking in nature and are subject to risks and uncertainties, and actual events or results could differ materially. Factors that might cause actual results or events to differ materially include, but are not limited to, those referenced in today's press release and in our SEC filings, including our Form 10-K, which you can access on our website. Also, on this conference call, you'll hear management refer to estimated positive or negative impacts stemming from COVID-19 during the third quarter of 2020. You'll also hear management discuss intra-quarter business performance for the month of October. Management is offering this commentary to give the investment community additional insights into trends, and these disclosures might not be made in later quarters. With that, I'll hand the call over to Liam.
Liam Kelly
executiveThanks, Jake, and hello everybody, it's great to be with you this morning — I trust all of you are staying safe and healthy. Taking everything into account given the conditions we're facing, our third quarter results leave us satisfied, since they showed the anticipated uptick in momentum across numerous of our worldwide product lines, driven by a swifter-than-anticipated bounce-back in our Interventional Urology segment, plus ongoing vigor in sales of our vascular access offerings. Regionally speaking, we noticed notable momentum in the Americas, as the speed of rebound in the United States across quarter three proved heartening. Third quarter revenues came in at $628.3 million, a drop of 4.1% versus the same period a year earlier on a constant currency basis, yet considerably stronger than the 12% falloff we saw in quarter two of this year. The year-over-year revenue drop stems from COVID-19's effects, which we calculate produced a net negative impact of roughly $78 million, or about 12%. Had we adjusted for that COVID drag, we figure our underlying business expanded roughly 8% on a constant currency basis, in line with what we delivered in quarter two; we likewise observed a substantial sequential gain in our adjusted gross and operating margins relative to the levels reached in quarter two. And our adjusted earnings per share of $2.77 for the quarter substantially surpassed what we had expected internally. That mirrors the ongoing rebound we witnessed as the quarter progressed, combined with disciplined management of operating expenses. Before I dive deeper into our quarterly financial results, I'm delighted to share that in October we signed a definitive agreement to purchase Z-Medica, a market leader in hemostatic products. We're glad to put capital to work for a differentiated product portfolio that capitalizes on existing Teleflex call points and is immediately accretive to our revenue growth rates, adjusted growth and operating margin profile and to our adjusted earnings per share. Now to a fuller examination of our third quarter results. As I noted a moment ago, quarter three revenue fell 4.1% on a constant currency basis and 3.1% on an as-reported basis. The revenue drop stemmed from COVID-19, which we estimate dealt a negative impact of roughly $81 million across a number of worldwide product categories. That was partly offset by roughly $3 million in extra revenue from our vascular access and other product categories, which saw modestly stronger-than-anticipated demand stemming from COVID-19. On the margin side, we delivered adjusted gross and operating margins of 57.2% and 25.1%, respectively; that equated to a year-over-year decrease of 140 basis points at the gross margin line and 190 basis points at the operating margin line. Even so, we recorded a sequential gain of 330 basis points on both the adjusted gross and operating margin lines versus the levels attained in quarter two. Looking at things compared to the same period last year, lower sales volumes stemming from COVID worked against us. That said, our efforts to keep costs in check provided some balance, since we keep trimming expenses wherever we judge it makes sense given today's conditions, while still funding the investments needed to support our longer-term growth goals. Adjusted earnings per share came in at $2.77, a decline of 6.7% versus a year ago, yet this beat what we had expected internally, as business activity kept improving through the quarter. If you set aside the drag that COVID-19 placed on our third quarter results, our estimate is that adjusted earnings per share would have risen roughly 13% against the same period last year. All in all, I feel quite good about how we performed financially, since it shows how resilient our diversified global product portfolio is. Now let's discuss quarterly revenue trends, and these will be presented on a constant currency basis. In the Americas, third quarter revenues reached $375 million, an increase of 0.4%. The growth in that region came from vascular access and respiratory products, both of which experienced higher demand because of COVID. Beyond that, Interventional Urology contributed strongly, with UroLift remaining among the procedures recovering most quickly; even so, declines in other product categories partially offset this. Our estimate is that the Americas would have expanded by about 9% if you remove the effect COVID-19 had there. EMEA posted third quarter revenues of $135.7 million, a decline of 7%. Over the quarter, most product categories saw declines, since rising COVID infection rates hurt procedures and results. If we adjust for COVID, our estimate is an underlying decline of roughly 3% for that region. Now turning to Asia; third quarter revenues came to $68.2 million, a decline of 14.2%; even so, our estimate is that we would have achieved positive constant currency revenue growth in the high single digits were it not for COVID-19's impact. Also, in the third quarter we started transitioning a distributor in Japan. Once you normalize for both COVID and that distributor change, growth for the region would have come in nearer the low double-digit range, in line with our longer-term outlook. Finally, our OEM business posted third quarter revenues of $49.4 million, which declined 11.8% on a constant currency basis. Just as we expected, our OEM business experienced a delayed COVID-related impact during the third quarter, in contrast with our other businesses. Those who invest in Teleflex know that our OEM business provides medical companies with complex catheters and surgical sutures, and the third quarter effect mirrors lower orders from those customers, whose business depends on non-emergent procedures. If you exclude the estimated COVID-19 impact, this business expanded by approximately 28%, which includes a benefit of about 11% from the HPC acquisition. Regarding HPC, I'm happy to say our integration work remains on track. Let's now discuss our revenue by global product category. We'll begin with vascular access. Thanks to expansion in our PICC and EZ-IO lines, third quarter revenue rose 6.8% to $160 million; we believe COVID-19 boosted our vascular products' growth rates by roughly 1% during that same quarter. Now on to interventional access; third quarter revenue came in at $93.2 million, a decline of 13.5% versus the prior year period. That drop stemmed mainly from delayed recovery in some non-emerging procedures tied to COVID-19, plus the negative effect of a catheter recall that took place in the quarter. We figure the recall hurt our business by about $4 million. Fallout from the recall will keep weighing on us over the coming several quarters, since we don't anticipate having this product back in the market before September of 2021. If we adjust for what COVID did to these product lines, we estimate underlying growth landed in the low single digits. Shifting to Anesthesia; revenue reached $75.7 million, trailing the prior year by 14.4%. This revenue decrease came from weaker sales of laryngeal masks, regional anesthesia and airway management products.
Liam Kelly
executiveWe figure COVID had an adverse impact of about 10% in the quarter, implying the business was down in the mid-single digits when you strip that out. Turning to Surgical: revenue declined 12.3%, landing at $82.2 million, driven mainly by softer sales of our ligation and instrument product lines; COVID is estimated to have been a 13% headwind in quarter three, indicating improvement compared with the roughly 30% COVID drag we estimate for quarter two. Moving on to Interventional Urology: quarter three revenue climbed 11%, reaching $81.8 million; we estimate a COVID-19-related headwind of approximately 29% in quarter three. Even with that big drag on our third-quarter growth, we're happy about the way this business unit is bouncing back, and we're pleased with how our national DTC campaign has performed so far — it's coming in ahead of what we expected. Another encouraging sign: we brought 120 new urologists through training in quarter three, which puts us back on a pace in line with our pre-COVID expectations. Lastly, our other category, which consists of our respiratory and urology care products, was up 0.5%, reaching $86 million. In our estimation, that increase for the quarter mostly came from stronger demand for certain humidification and breathing products tied to COVID-19. On a monthly basis, September came in stronger than both July and August once you adjust for the distributor termination and the product recall in our interventional business. In addition, during the opening weeks of October, we keep seeing slight further gains relative to the same month last year; even so, given how sharply COVID cases have risen around the world, and after adjusting for selling days, we anticipate a small uptick in constant currency revenue results for quarter four, versus the 4% decrease we posted in quarter three. Tom will share more specifics afterward. That wraps up what I have to say about third quarter revenue performance. Now to a few recent clinical and commercial updates. Let's begin with UroLift. The results we're seeing from our national DTC campaign are better than we had anticipated. DTC plays a key strategic part here, since roughly half of the 12 million men receiving treatment for BPH are under the impression that prescription medications represent their sole option. So far, we're on pace relative to our goal of producing six times the impressions that the regional campaigns delivered in the same period a year ago. Since launch, web traffic is up more than 150%, and one more encouraging sign is that a number of urologists are now eager to receive training on UroLift because patients have been asking about it thanks to the campaign. Also, although the effect on Q3 numbers was probably minimal, we anticipate the campaign's momentum will keep growing through quarter four and into the beginning of next year, since we're dialing advertising back up to full strength starting in early September. Moving on to UroLift 2: following the July 31 FDA clearance, we've launched a market acceptance test and gotten encouraging early feedback, such as improvements to the delivery device's triggering mechanism and less waste. On top of that, we're increasing manufacturing output ahead of the full commercial launch, which is set for early in 2021. Now, regarding the UroLift ATC. We recognize that the market acceptance test is actively progressing, and the feedback we've gotten has been quite favorable, suggesting that the device is fulfilling its intended purpose of providing better tissue control when addressing difficult anatomies like obstructive median lobe. When we put all this together, we believe these initiatives are aiding in generating momentum as we aim to broaden our leadership role in BPH. Moving to the next slide covering important commercial updates; we've just obtained a broader indication for EZ-IO, meaning the device is now approved for use for as long as 48 hours when our alternative intravenous access isn't feasible in adults as well as pediatric patients who are 12 years or older. While we don't expect this label expansion to drive a big jump in sales, we are always working to strengthen what we offer based on feedback from clinicians, and this is a good example of that kind of effort. Last, I'd like to give the investment community a few more details regarding the Z-Medica acquisition we told you about last night. In mid-October, we reached a definitive agreement to acquire Z-Medica, a leading player in the hemostatic products space. Under that agreement, Teleflex will pay $500 million upfront for Z-Medica, along with up to an additional $25 million contingent on hitting certain commercial milestones. As part of this deal, Teleflex will also obtain certain tax attributes that should lead to future tax benefits. We estimate these tax attributes to be worth around $40 million, which factored into our determination of the purchase price. Z-Medica's hemostatic technologies are contributing to a transformation in hemorrhagic control, with affordable and effective bleeding control solutions being embraced by markets globally. The company provides three primary brands: QuikClot, Combat Gauze and QuikClot Control+, which rely on proprietary technology made up of gauss impregnated with calin. This technology triggers and speeds up the body's inherent clotting capacity. Right now, Z-Medica's products are mainly focused on trauma surgery, EMS, the military, emergency departments, and interventional areas, and there's potential to expand into additional indications down the road. At Teleflex, our strategy is to put money into innovative products and technologies capable of delivering meaningful gains in clinical outcomes, patient safety, and comfort, while reducing complications and lowering the overall expense of care. By bringing Z-Medica on board, Teleflex can leverage what we do well across hospital, EMS, and military call points, using differentiated products that fit neatly alongside our EZ-IO and EZPlas lines. This acquisition has us excited, since it could drive revenue growth above the company average, as well as gross and operating margins that come in higher than the company average. Subject to obtaining certain regulatory approvals, the deal is anticipated to close in the fourth quarter of this year. Looking ahead, the transaction should add between $60 million and $70 million in revenue and between $0.07 and $0.15 in adjusted earnings per share for fiscal year 2021. Looking past 2021, we anticipate that this acquisition will produce revenue growth in the high single digits, along with additional accretion to adjusted earnings per share. Regarding EZPlas, following our recent discussions with the FDA, we decided to move forward with the BLA submission instead of an EUA. We are still working in close partnership with the agency to establish when that submission will occur. On the whole, our dedication continues toward putting money into clinical and commercial catalysts through internal means, since those drive the revenue growth targets we have set for a normalized environment. Beyond that, we plan to add to those in-house efforts by directing capital into external growth possibilities, Z-Medica among them. That concludes what I had ready to say. Right now I want to pass things along to Tom, who is going to walk everyone through a fuller look at the financial results for our third quarter. Tom?
Thomas Powell
executiveThank you, Liam, and good morning to all of you. Since we already covered how the company's revenue performed, I'll pick things up at the gross profit line. Adjusted gross profit for the quarter came in at $359.6 million, compared with $380 million in the same quarter last year, which works out to roughly a 5% decline. Adjusted gross margin for the quarter was 57.2%, down 140 basis points from the prior-year period. The main driver behind the gross margin drop was COVID-19 related effects, such as lower sales volumes and increased manufacturing costs, plus a foreign exchange headwind. Volume had a big effect this quarter, because the negative revenue impact from COVID-19 skewed toward products carrying higher gross margins, including Interventional Urology, Interventional Access and Surgical. All told, we estimate COVID-19 cut our adjusted gross profit by about $59 million this quarter. We keep managing discretionary spending tightly to partly offset the revenue and gross profit lost because of COVID-19, and thanks to those efforts, we estimate operating expenses came down by roughly $22 million in the third quarter. Although we anticipate that the steps we've taken will keep producing OpEx savings for the rest of the year, the biggest quarterly OpEx reduction by far occurred in the second quarter. Adjusted operating profit for the third quarter of 2020 reached $157.6 million, versus $175.3 million a year earlier, a decline of approximately 10%. Operating margin in the third quarter was 25.1%, down 190 basis points year-over-year, mainly because of the gross margin decline. And while our adjusted margins declined in the third quarter relative to the year-ago period, we're glad to see gross and operating margins improve sequentially from the lows we saw in the second quarter. Looking ahead, we anticipate further sequential margin improvement in the fourth quarter. Net interest expense came to $16.4 million, down approximately 14% from the prior year. That drop in interest expense mainly reflects lower average interest rates on our variable rate debt, partly offset by higher average debt balances than in the prior-year period. Now to taxes for the third quarter of 2020: our adjusted tax rate was 7%, compared with 10.3% in the prior-year period. The year-over-year decline in our third quarter adjusted tax rate stems mainly from a favorable mix of taxable income relative to the prior-year period, along with a bigger benefit from stock-based compensation than in the prior-year period. On the bottom line, third quarter adjusted earnings per share fell 6.7% to $2.77. This result includes an estimated COVID-19 adverse impact of roughly $0.60, plus a foreign exchange headwind of about $0.09. Now for a few balance sheet and cash flow highlights: in the first nine months of 2020, cash flow from operations was $241.5 million, compared with $289.2 million in the prior-year period. That drop comes from bigger contingent consideration payments, though that was partly offset by positive movements in other working capital thanks to stronger collections of accounts receivable. All in all, the balance sheet is still in solid condition. When the third quarter closed, we held $347.5 million in cash, compared with $553.5 million when the second quarter ended. Across the third quarter, we paid down close to $285 million on our revolver borrowings and brought revolver availability back up to the complete $1 billion. At the close of the quarter, net leverage stood at roughly 2.6 times. We project that buying Z-Medica will push net leverage up by under three quarters of one turn, and on a pro forma basis for that acquisition, net leverage stays well beneath the 4.5 times covenant. Our plan is to fund the Z-Medica purchase through revolver availability, though we might opt to permanently finance this acquisition via a future notes issuance. Finally, we face no near-term debt maturities of significant size. Because uncertainty persists regarding how the COVID-19 pandemic will affect business operations, we are not bringing back financial guidance right now. That said, we will give these directional expectations for the fourth quarter. Going forward, we still anticipate additional sequential gains in our constant currency revenue performance relative to what we delivered in the third quarter. Yet with global COVID-19 cases surging again across the last seven to eight weeks, we anticipate our constant currency revenue growth will only be somewhat better than what we delivered in the third quarter. This outlook for a modest fourth quarter gain leaves out the advantage of two extra selling days that fell in the fourth quarter of 2020, which we calculate would contribute roughly 3% in additional revenue growth during the fourth quarter; and this outlook likewise leaves out any advantage from the Z-Medica acquisition, since the closing date has not been set. That wraps up my prepared remarks, and now I would like to hand the call back to Liam for closing commentary. Liam?
Liam Kelly
executiveAppreciate it, Tom. To wrap up, our third quarter performance came in strong, with the diversified portfolio delivering the ongoing anticipated gains versus quarter two on both revenue and earnings. If we set aside COVID's effect, the underlying performance of the business looks encouraging and aligns very closely with what we originally expected. We still regard the global COVID resurgence, taken together with the readiness of more vulnerable individuals to undergo procedures, as the leading wildcards affecting the recovery. Although uncertainty will touch the coming quarters, we stay confident about our capacity to execute as we move toward 2021, and we feel good about our longer-term outlook. As an organization, we'll keep our attention on serving hospital customers and collaborating with key stakeholders. We'll run the business carefully while remaining concentrated on capturing the long-term opportunity in our worldwide product portfolio. Finally, I'd like to express gratitude to every one of our employees who keeps manufacturing, distributing, and supporting the products needed in the battle against COVID19, with a focus on honoring commitments to patients, clinicians, communities, and shareholders. That brings my prepared remarks to a close. At this point, I'd like to hand the call back to the operator for the Q&A.
David Lewis
analystMorning, and thank you for taking my question. Liam, it's fairly evident that visibility into the business has slipped somewhat since our September conference. If you're able, I'd like to break out what you believe those drivers to be, since it sounds as though this occurred a number of weeks back, not merely within the past 48 hours. So would you characterize it purely as an absence of gains in US hospital census? Is it overseas markets, particular overseas markets that are softer, or the OEM segment, which maybe enjoyed early advantages that weren't sustained? Yet given that these matters have likely persisted for a number of weeks rather than a number of days, I want to break out what specifically you consider to be the weak spot in the business. And then, Tom, just so I'm clear regarding the guidance, we ought to be assuming low single-digit organic decreases during Q4; and then I have just one brief follow-up.
Liam Kelly
executiveAll right, David. So to begin, in my view our underlying business is in fact doing quite well. Looking at Q3, we posted growth of 8% despite a few headwinds beyond COVID, and that 8% figure leaves out COVID; therefore, if you examined how our underlying business performed, we're nearer to 9% once you strip out the Langston recall and strip out the go direct in Japan, which will deliver longer-term advantages for us. My view across the last number of months hasn't shifted, to be completely candid with you, even though I am watching COVID deteriorate. When I came to your conference, I believe I was quite clear that while a number of our peer companies anticipated a recovery during quarter four, we did not anticipate that recovery until early in 2021, and my thinking on that point remains unchanged. Before Tom speaks about quarter four, I believe it matters that I share with you and the investment community how we're thinking about revenue growth during the fourth quarter. A lot of you who know Teleflex will be aware that we've been observing, as I mentioned, over the past couple of months that we anticipate the recovery arriving in early 2021 rather than in the fourth quarter, and we still hold that view. And as I stated, David, my thinking hasn't shifted. But because infection rates have risen substantially around the world, we're now more cautious regarding how quickly the recovery comes, even relative to a few months back; in working out what we believed would unfold in the fourth quarter, we projected the modest year-over-year constant currency revenue growth improvements that we witnessed in October across the whole quarter. What we failed to account for was a pickup in elective procedures, higher patient volumes stemming from DTC, and we also didn't account for the second shift down tied to COVID, which in our view is highly unlikely. We certainly factored in how tough the comparison was versus Q4 of the prior year, when we posted a fairly strong quarter, and our view is that this is a well-balanced stance. So we arrived at the conclusion that constant currency revenue growth in Q4 would show a slight step up from Q3 once you set aside the billing days, and naturally the billing days then contribute roughly 3%. So really, David, I think it comes down to what we're observing in end markets around the world — the rise in COVID we're seeing in countries such as France, Spain, Italy, Australia and Southeast Asia, plus the important market that is the United States. And I should say I felt genuinely encouraged by how our US business performed in the third quarter, where North America has moved to positive growth of 0.4%, and that figure would have looked even stronger were you to strip out that one-time Langston call. But I'll hand it to Tom to speak about the fourth quarter.
Thomas Powell
executiveRight. So, Liam, I believe you hit on the main items, and during Q3, our growth in currency terms declined 4.1%. Like we said, absent the gain from additional shipping days plus the Z-Medica acquisition, we anticipate that constant currency growth for Q4 will be just slightly improved relative to that. Therefore, without giving an exact figure, we don't anticipate any major uptick in constant currency growth as we move from Q3 into Q4.
David Lewis
analystAlright, that's really, really useful. I've got just a couple of fast questions, then I'll get back in line. Liam, on UroLift, that business keeps getting better. Could you help break out what DTC is contributing to the underlying business? With the COVID headwinds it's sort of tough to tell, but do you sense we're building DTC momentum as we move from the third to the fourth quarter? And then on Z-Medica — interesting market, very profitable asset — help us see how you approached valuation and returns. Thanks a lot.
Liam Kelly
executiveYes, of course. Starting with UroLift, clearly a great return to growth, up 11% in quarter three. Like I mentioned before, we haven't factored any DTC uplift into our quarter four thinking. Are we pleased with how DTC is performing? Without a doubt. It's going extremely, extremely well. Patient response is beating expectations, web traffic is up 150%; we now actually have urologists approaching us wanting training on the UroLift, since patients are walking into their practices and asking about it. This isn't market research, David, but during this past quarter I spoke with 28 urologists, and 27 of those 28 said patients had come into their practice asking about UroLift directly because of something they saw on a TV or web campaign. So that leaves us very encouraged. On the Z-Medica acquisition, let's begin with the strategic piece we always examine — does it belong inside Teleflex? Yes. The call point sits exactly where we want it, EMS and trauma. Does it hold IP? Yes, very strong IP extending out to 2033. Are synergies there because we're bringing it into our portfolio? Certainly. Does it have outstanding clinical efficacy? Yes, 150 clinical papers have been written on it, and it's a highly sticky product moving into a market worth $600 million globally, with room to grow overseas. As for valuation, a few of the key metrics we reviewed — clearly the revenue multiple sits in the mid-7s on forward revenues. But once you strip out the tax attributes, it's only about 7 times. Then, more significantly, on an EBITDA basis it's in the high teens of 2021 EBITDA, and in the lower teens going into 2022. We'd view this as a scale acquisition comparable to Vidacare. We really like the accretion, and it's accretive to our top line growth, accretive to our gross margins, and immediately supportive of our longer-term op margin goals; plus it beats our internal cost of capital by year four — by the close of year four. Once more, a solid target we aim toward — as you're aware, that's the standard we attempt to establish for ourselves — involves reaching a point past our internal cost of capital by the fourth year, and just so it's clear, that internal cost of capital sits in the very high single digits.
David Lewis
analystOkay. Thanks so much.
Liam Kelly
executiveThanks, David.
Larry Keusch
analystThanks. Morning, everybody. Liam, I wanted to ask — circling back to UroLift, I suppose there are two things here. How are procedure trends shaping up when you consider those performed in the hospital against those performed outside of it? I'm curious whether that keeps drifting higher. And then, when it comes to the fourth quarter, how do you view UroLift's underlying growth once you set aside the two selling days? Do you expect that you'll keep seeing growth improve sequentially, especially once DTC takes effect? And then I have a few quick ones on Z-Medica.
Liam Kelly
executiveAll right, Larry. So, on UroLift, for your first question regarding site of service, a shift away from the hospital toward outside of the hospital, and specifically toward office settings, is something we keep observing. That has shifted roughly 4 percentage points — moving from the office to, sorry, from the hospital to the office; when it comes to the recovery, there's also a notable difference between how the office setting and the hospital setting are recovering. In the third quarter, we see the office setting as fairly positive relative to pre-COVID levels, while for UroLift procedures the hospital setting remains below pre-COVID levels. So obviously, procedures being relocated into the office environment has compounded that. As for shifting to the fourth quarter and looking at UroLift there, as you know, Larry, UroLift has got a significant — had a significant accomplishment last year. Last year it grew 64.4%. So heading into the fourth quarter, they face a really tough comp. Even so, if I look at it sequentially on an absolute dollar basis as we move from Q3 to Q4, we would definitely — our expectation would be to see a higher dollar value as we go from Q3 to Q4; and as I mentioned in my earlier remarks, Larry, forecasting the absolute impact of DTC in the COVID environment is very hard. So, given the uncertainty around COVID, we haven't really built an expected DTC impact into the fourth quarter; that said, the DTC campaign is going exceptionally well; we will definitely be on track to get 6 times — a multiple of 60 impressions compared with what we got last year when we did our 18 regional DTCs. As I said, our web traffic is up 150%. The number of patients who are actually going to our doc finder and coming to our call center — I won't give you that number, Larry, for competitive reasons, but I can tell you that what we're seeing happen out there with the DTC is very encouraging.
Larry Keusch
analystAll right, excellent. Moving on to Z-Medica — clearly, the price tag matched what it was before and seems appropriate for an organization growing at a high single-digit pace. Yet, what's your take on how long that expansion can last, and what makes it sustainable? I'm assuming it stays up in that high-single digit territory. The second part of my question is: what are your thoughts regarding revenue and expense synergies from this asset, and what assumptions went into the deal model? Thank you.
Liam Kelly
executiveSure thing, Larry. Excellent question. From a growth standpoint, to start with, the end markets here sit right around the 4-ish-percent zone — 4% to 5%. That means simply by showing up, you're picking up decent growth, which is a bonus too. The market sizes are also quite promising. Globally, the total market comes to roughly $600 million, with $150 million in EMS, more than $300 million in trauma, and $125 million in Interventional. There's also a chance we have — and it's factored into our model — to conduct additional clinical work aimed at extending it into cardiac down the road, which would grow that market further still. On top of that, at present the revenue comes mostly from North America — somewhere between 80% and 85% of revenues are North American — so we see going overseas as a major opportunity, leveraging our channel, which, as you're aware, is central to our strategy. The active part, we'll hit about $50 or $60 million in the prior year, and $60 to $70 million in the current year; plus, one thing investors shouldn't overlook is that this asset's gross margins fall in the low-80s. That gives us a solid chance to keep pushing our margin expansion, and it also shouldn't be forgotten that the op margins, before synergies, are accretive against our longer-range op margin targets. We ought to be able to produce roughly $10 million in synergies by year three from this asset, which will further support op margin expansion. When you pair that with the growth, it becomes a really thrilling acquisition for us; and honestly, Larry, I'd view this as a second Vidacare. Quicker growth, excellent margins, plus our ability to capture synergies and keep growing it abroad and across additional segments.
Larry Keusch
analystAll right, and I just want to make sure I have this right — the $50 million to $60 million of revenue you mentioned, and then the $60 million to $70 million, is that for 2019 and 2020? Or how exactly should we be looking at it?
Liam Kelly
executiveThat's the 2020 level...
Thomas Powell
executiveSo the figures Liam brought up — those 2019 figures of $50 million to $60 million and $60 million to $70 million — that's what we're expecting for 2021.
Larry Keusch
analystAll right, that's clear now. Appreciate the explanation.
Liam Kelly
executiveYou're welcome, Larry.
Richard Newitter
analystThank you for allowing me to ask. To kick things off, when you look toward the coming year and consider the catalysts you've outlined, you brought up EZPLAZ and the BLA route. Could you offer some clarity on when you expect that regulatory path to move forward? Also, please address the expected timeline for UroLift Japan. And could you speak to what's happening with Manta's underlying trends — particularly since it seems to be involved in certain procedure types that are now being performed on a more urgent basis? Do you have any view on how that trajectory could unfold across the fourth quarter and into 2021, compared with other areas of your business where you're somewhat more cautious?
Liam Kelly
executiveWith respect to UroLift Japan, our position hasn't shifted since the prior update; we expect reimbursement during Q2, and revenue generation in Q2 and Q3 of 2021; so there's no change on that front for UroLift in Japan. On the BLA side, Rich, we've advanced quite well with the FDA. At one point we were evaluating an Emergency Use Authorization — I believe the military engagement there was quite beneficial for us — and at this point we expect to file a BLA. Are we more confident today about producing revenue at some point in 2021? Yes, we are. The exact BLA schedule still needs to be settled with the FDA, and after the BLA is in place we move onto a fast track, and it hinges heavily on the timing of their approval, but I'm fairly optimistic that EZPLAZ will reach the market at some point during 2021. As for your Manta question: Manta had a strong third quarter in North America, getting back to growth at roughly the 20% level in North America during Q3, and that encourages us greatly. This product — it opens doors for us into hospitals, and clinicians are eager to adopt it since it shortens the time to hemostasis; and in the current climate, when you're pushing more TAVR cases through the cath lab, that matters a great deal. So we view Manta as one of our main growth drivers heading into 2021. One among several, I should note, Rich. We have UroLift, we have Manta, we have UroLift Japan, we now have Z-Medica, and we have EZPLAZ coming along. So there are numerous growth catalysts ahead as we enter 2021, and that's quite encouraging; we simply need to get past this COVID period. And regarding your remark that we're more cautious than before — I'd say, Rich, that isn't the case; our level of caution matches what it was a couple of months back. Our view remains that a bounce back from COVID won't show up during Q4. We're figuring it will arrive close to 2021, and our perspective on that hasn't shifted at all. That said, I appreciate the questions.
Richard Newitter
analystUnderstood; and regarding that final point, if I may ask a follow-up, Liam, about the last section on 4Q. So, I suppose what I'm gathering is, you have certain factors that might be incrementally favorable compared to what's baked into your internal forecast, such as the DTC advantage. Yet you're also mindful that surgical procedures are happening within the US and even more substantially abroad. So, perhaps we should interpret that as you haven't really observed that effect on elective surgeries or hospital patterns as of yet, with October trending higher than the third quarter's trajectory. However, you're going to exclude any additional gain past October, or in fact you're moderating, and the possibility that circumstances regress, which explains why the enhancement has been larger in 4Q.
Liam Kelly
executiveSo, I believe, the manner — it's an excellent question, Rich. I believe, the manner we see it, well, September on an adjusted basis was approximately minus 2%. And we noticed a sequential gain during the initial weeks of October. And in fact the initial weeks of October were essentially level compared to the same period last year. Yet in spite of this encouraging movement in October and because of the surge in COVID cases and the more difficult comparables, we continue to anticipate slight enhancement in Q4 relative to Q3. We haven't included, as you mentioned, the DTC, perhaps we're erring on the side of caution; but this is the most transparent view we possess at present, and should the rebound persist in Q4 as we haven't included, Teleflex will gain from that and we will speed up. Should we enter a second lockdown, which I don't anticipate, it won't be more severe than we predict. However, I believe we're attempting, Rich, to adopt a balanced and careful strategy for the fourth quarter. And based on what's currently before us, as I've mentioned several times, my ability to predict is less clear than it has ever been with 2 months remaining in a quarter. Still, I'm heartened by what I observed in October, Rich, frankly. We face a very difficult comparison during the final 2 months, and we have not included an ongoing enhancement in recovery; we've essentially taken what we witnessed in October and distributed that across the final 2 months of the quarter. Now, should it keep recovering, it will be superior, there's no question about that.
Richard Newitter
analystUnderstood. Now, Liam, I just want to make sure — the Q4 outlook you gave us, none of that assumed anything coming from Z-Medica, right?
Liam Kelly
executiveRight. I mean, several factors are going to assist us in getting there, and Z-Medica is one you just mentioned. Currency movements ought to be a tailwind for us. Should procedure volumes begin recovering somewhat, that would also be a boost. So yes, that's right. Z-Medica wasn't factored in, and on top of that, Q4 gives us 2 extra billing days, which ought to contribute roughly 3%. So there are positive signals and good openings, but we don't want — from where we stand today, our aim is to be completely straightforward with the investment community.
Richard Newitter
analystThanks.
Shagun Singh
analystI really appreciate you taking my question. First, a quick clarification about Q4. With those two additional selling days, is it fair to anticipate that Q4 turns positive for you? Then a few things on UroLift — from what I understand, the initial group of patients began coming in during September and October. Could you tell us what magnitude of volume increase this effort is generating? And thinking ahead to Q4 — thanks for all the detail on that — you'll have a whole quarter of the national DTC campaign, and you mentioned you haven't yet reached 6 times the prior-year ad impressions; meanwhile, on an underlying basis, through the year so far, you've been running at roughly 40%. So would that be a sensible floor to assume for Q4? Thanks.
Liam Kelly
executiveShagun, I believe you've got that right. The underlying results across every one of our businesses have us quite encouraged, and UroLift is certainly part of that. That underlying figure has held pretty steady at 40%. The reason we haven't factored DTC into Q4, Shagun, is straightforward: it's extremely difficult for us to figure out where a patient originated once they arrive at the urology practice, and there's also uncertainty tied to COVID — case counts rising across the United States. As for disclosing details of the DTC campaign, Shagun, competitive considerations make it unwise, in my view, to reveal much of the specifics, though I can say the count of patients who click and phone our call center has us quite encouraged. Were all of them to convert into a procedure — which won't occur — that would leave us as an organization feeling quite encouraged; moving into Q4, as we noted previously, we were down 4% during the third. We anticipate a slight gain relative to that, and beyond it we anticipate gaining another 3% from billing days. If FX holds at today's levels, it ought to help us. That's how we see Q4 finishing.
Shagun Singh
analystUnderstood. That helps. Now, could I ask one thing regarding 2021? You said a moment ago, I believe, that several quarters ahead will bring COVID-related uncertainty. What does that imply for 2021? The consensus, as I understand it, is roughly double-digit growth for 2021 compared with 2019, and I think that still sits under pre-COVID levels. So how do you respond to that? Then, regarding margins, what's the right way to look at them? Also, when do you think you'll reach your LRP goals? Thanks for taking my questions.
Liam Kelly
executiveThank you, Shagun. For us to address the bulk of what you asked, we'd need to be past COVID. The uncertainty surrounding COVID is enormous. Does the underlying performance of our business encourage us? Without a doubt, the underlying performance of our business encourages us. Do we believe multiple growth catalysts exist? Yes. Did we add yet another one just today? Yes, Z-Medica has been added. Do we believe Teleflex will be strongly positioned once we are past COVID? Yes; as for our longer-term goals, are those the right goals for Teleflex? Without a doubt, they are. My thinking on that hasn't shifted at all either; for Teleflex, those are the right goals. Whether we reach them isn't the issue — the issue is when. Still, to give the investment community clarity on that point, we must be past COVID. We need either a vaccine or a decline in the level of the condition down to some point where consumer confidence is elevated and hospitals can achieve greater patient throughput. Although at the start of this COVID crisis everyone anticipated something close to a super boom in Q4, with hospitals adding extra capacity, October has not shown that; and my expectation is that November and December won't show it either. I also don't want to base the fourth quarter on a super boom of procedures returning to hospitals, because honestly, I cannot see that occurring.
Shagun Singh
analystThanks a lot.
Anthony Petrone
analystHello. Morning, everybody. Hope you're all doing well and staying healthy. I've got two questions for Liam, and after that a follow-up for Tom. Those first two are about UroLift, and I'd like to know if you can update us on how many urologists have been trained in total so far? Based on our calculations, that figure sits at roughly 2,800, possibly a bit above that. Then, given the 12,000 urologists practicing in the US, perhaps you could refresh us on what the peak target penetration is within that group. One more quick UroLift item would be anything regarding the DOJ investigation. After that, I'll move to the follow-ups. Thanks.
Liam Kelly
executiveOkay, Anthony; regarding the DOJ, there's really nothing new to share, and my advice to the investment community is not to anticipate any news for several quarters, since their attention remains on that one practice. As for how many urologists, Anthony, things have shifted, and your calculation is fairly accurate. Of the 12,000, we've trained somewhere around 2,900. What I find really encouraging is that 120 urologists were trained by us during the third quarter, which puts us right back at our normal run rate for training urologists prior to COVID. And I truly — well, I'm certain the DTC is contributing to this, since we know urologists are approaching us because their patients are walking into their offices and asking about UroLift. The second part of what you asked, about those 12,000 urologists, how many must we train? What number does the trick? Through our research, when we segmented our champions, we found that the typical urologist treats 75 BPH patients; however, we also found that it makes no difference whether you're seeing 50 unique BPH patients each month or 150 unique BPH patients each month — your chance of becoming a champion stays the same. A champion, by definition, is a urologist performing at least six procedures per month. So essentially all 12,000 urologists need to be trained for us to reach 100% penetration. That's exactly why this is so exciting, Anthony, because the opportunity is enormous. The more urologists we train and the more BPH care becomes standardized around this, the bigger the market we can expand into.
Anthony Petrone
analystThanks. That helps. Now, two quick follow-ups. We saw that APAC trends from the second quarter to the third quarter actually slowed down — again, the thinking being that they're somewhat ahead of the curve when it comes to COVID. So maybe just address what really took place in APAC during the third quarter. And then Tom, regarding the final slide in the deck on the margin outlook: the total pre-tax savings target is $85 million to $98 million. I believe that as you exited 2019, $26 million of that had been realized. So perhaps just an update on where you stand regarding realizing the savings you expect from restructuring? Thanks again.
Liam Kelly
executiveYes, Anthony. I'll handle the APAC one. Clearly, APAC was affected by our choice to take the Japan business direct. So, normalizing for that, it came to roughly 11%. If you normalize for COVID, it was in that very low double digits, but around 11% — a slight decline, and that was really caused by a rise in COVID cases in India and Southeast Asia, plus a resurgence in Australia. We're a bit unique, I suppose, in that we have more exposure to Australia. It makes up a larger portion of our APAC business than would be the case for other companies, and similar to India. So those are the main drivers for APAC. And I'll let Tom respond to the other part of the question.
Thomas Powell
executiveOkay, regarding the restructuring efforts — first off, I want to mention that even with the COVID outbreak happening, the program is still on track with what we planned and scheduled. So we're feeling quite good about it. Actually, one of those initiatives got accelerated, and we'll be able to capture some of those savings sooner across the coming couple of years than we'd originally thought. Altogether, those savings come to $85 million to $98 million, like you said. By the close of 2019, roughly 25% of them had been realized. Then in 2020 and 2021, we anticipate realizing a pretty meaningful chunk, somewhat less in 2022, followed by a fairly considerable amount in 2023. So in terms of the cadence — for what's left, you'll see roughly half of it realized in 2020 to 2021, with the remainder coming over the next three years. Does that help?
Anthony Petrone
analystThank you.
Liam Kelly
executiveYes.
Matthew Mishan
analystHi Liam, regarding Z-Medica, could you back up a bit and walk through what sets this technology apart from rival offerings, plus the clinical data behind the expansion?
Liam Kelly
executiveSure thing, Matt. There are several clinical papers out there covering the 75 peer reviews, and it really boils down to a handful of core points. Take the human data — 88.3% successful hemorrhagic control, success rates that rank right at the top. Then consider the military study on Combat Gauze, which showed a greater rate of achieving hemostasis: 89% for the first attempt and 100% on the second application, versus standard gauze; so you're seeing 89% and 100% hemostasis against standard gauze at zero percent and 13%. Also, when it comes to blood loss in trauma, notably less bleeding after packing occurred, and that's the QuikClot plus, which can be placed internally, clearly cutting blood loss. Beyond that, an external use study in radial access demonstrated hemostasis shortened by 94 minutes to TR — versus the TR band. So hemostasis and time are truly what the clinical peer reviews center on; the product beats the standard of care currently used in the market and is being taken up quickly across EMS and trauma centers throughout the United States especially, and we aim to grow that internationally.
Matthew Mishan
analystAll right, that's great. Then for the final question, in what way are you precisely gauging how COVID has affected your operations?
Liam Kelly
executiveWell, if it's okay with you, I'll turn that over to Tom, since he's been collaborating with the finance group and the business units to sort through exactly that.
Thomas Powell
executiveAlright, then. Allow me to take you through how we did this. And I should say upfront—we recognize this isn't a flawless calculation. But as a company, we needed to grasp what the effect was, so we could make sense of our trends. I've devoted a good amount of time concentrating on this, and now I'll lay out our method for you. Basically, our starting point was the budget, after which we applied corrections for identified variances from that budget. We factored in positive or negative movements relative to the pre-COVID budget to gauge how individual businesses were doing, shifts in the competitive landscape, programs and events that got called off, along with CMA programs. We also examined back order positions and any movements there that might influence the outcome. We reviewed how distributors were placing orders, and even what customers told us about pushing orders out. So we drew on all these inputs to build a set of adjustments tied to COVID. The remaining gap from budget, after netting out those adjustments, was what we credited to the COVID effect. We also brought in additional methods to cross-check and confirm that figure. On the margin side, after nailing down the revenue effect, we were able to layer in our variable manufacturing costs. We factored in COVID-driven manufacturing cost increases, whether from social distancing, PP&E, attendance, and so on. We also adjusted for items like sales commissions, along with the OpEx cost savings initiatives. That sums up our method. I believe we've examined this very rigorously, while acknowledging it's not an exact science—it's simply our best estimate of the impact, and I hope that comes through.
Matthew Mishan
analystUnderstood. And thank you for the detail.
Thomas Powell
executiveYes.
Liam Kelly
executiveThank you, Matt.
Analyst
analystGood morning, everyone. Drew here, filling in for Matt. I appreciate you taking our questions. I was hoping to dig a bit deeper into that Z-Medica deal — congratulations, by the way, on securing what look like some genuinely compelling products. Could you perhaps elaborate on the possible sales force efficiencies? They appear as though they might be quite substantial. And after that, what kind of timeline are we looking at for training your sales team prior to launching it across the large majority?
Liam Kelly
executiveRight, so in fact, when we look at sales force synergies, we view them as synergies that Teleflex delivers, given the channel we have into EMS. With that in mind, we possess a highly capable sales team marketing EZ-IO, marketing laryngeal masks, marketing an entire range of products into that EMS and military call point, and our ties with the military are extremely solid, which you can observe through their co-sponsorship of the EZPLAZ product to bring it to market. So we regard that as a real chance for us to speed up growth within that key call point. And following that, to broaden our reach across the remaining trauma segments. As mentioned earlier during this call, we anticipate total synergies of roughly $10 million by year three, and that stems from multiple areas and represents an opportunity for us. However, we want — this is a growth asset, and our view is that we'll keep investing behind it in the channel going forward so we can be sure there will be a greater number of sales people on the ground within the combined organization than existed when Z-Medica operated as a stand-alone; plus we'll aim to grow into our overseas channel; we likewise hold a direct call point into certain of these key areas abroad, along with opportunities there to grow this portfolio. So it's a really attractive acquisition — high single-digit growth, excellent margins on both gross and operating margin. Strong clinical data and very lengthy IP, so it's well protected and expanding into a $600 million market.
Analyst
analystAll right, that's quite useful. My next question concerns how the Other segment performed — from what I understand, that's where your respiratory operation sits, and it got a lift from COVID at the start. It seems as though it came back to flat during this quarter. Should I interpret that as some of those early COVID tailwinds beginning to fade? Or could it tick up somewhat once more, given how severe the present COVID outbreak is? Thanks.
Liam Kelly
executiveRight. What you'd anticipate happening is this: once you move past the rise in the COVID curbs <<inaudible>>, which is what occurred in Q3, precisely as you noted, Drew, you'd expect those operations to revert to more typical levels. Moving into Q4, with COVID starting to climb once more, you'd expect our respiratory as well as our vascular operations to gain from that climb. Ordinarily, we'd expect a robust flu season to help respiratory. In my personal opinion, the flu season this year doesn't matter, because of COVID, and hospitals will safeguard themselves by holding supplies of these products during the fourth quarter, in case the resurgence carries on and in case we enter a second lockdown. My belief is that a second lockdown won't happen, Drew — I think hospitals have genuinely figured out how to care for COVID patients; they're additionally separating areas within hospitals, or even whole hospitals, so COVID patients can be moved there, allowing them to keep performing procedures even while a second COVID outbreak is underway.
Analyst
analystThanks.
Analyst
analystHey, everyone; Young <<inaudible>> here, filling in for Matt. Given time constraints, I'll keep it to a single question, and it's fairly high level; I'm curious about your expectations for when the operating environment might return to normal once we're past COVID, say, after a vaccine has been broadly rolled out. I know the path forward is pretty uneven, and it's a difficult question, but I'd just like to hear your perspective. Assuming we reach 75% herd immunity through vaccination, could business trends get back to pre-COVID levels possibly even sooner than that, or one or two quarters later? I'd just like your high-level view on that.
Liam Kelly
executiveWell, looking at quarter three, we observed things starting to normalize until COVID cases surged, first in Europe and then in North America. So during quarter three, as it progressed, we were moving toward that, particularly in the first couple of months of quarter three; then, in the third month of quarter three, we saw COVID cases climbing once more. I believe the response to that question is, first, get past COVID in Q1, Q2 next year, then get a vaccine; and I think there's also somewhat of a psychological element in people sensing that a vaccine exists. As a result, they'll feel more at ease resuming and having procedures performed, and they won't be as worried about a second or a third wave as would likely be the case at that point; so, I think the vaccine is essential, I think the virus itself weakening and being managed better is also essential as we head into the first half of 2021. And I'd be quite hopeful that if we make it through the first half of 2021 and early in 2021, we'll start to emerge on the other side of this COVID pandemic with a vaccine available and begin getting back to some sense of normalcy. But then again my crystal ball is as clear as yours is at this moment, everybody's crystal ball is somewhat murky.
Analyst
analystAll right, thank you. That's quite useful.
Dave Turkaly
analystGreat, thanks; and I don't want to keep harping on this, but you brought up France, Spain, Italy, Australia and the US, the rise in cases. I'm just wondering, anecdotally, whether you've observed any sign of elective procedures being deferred in any of those places right now. I'm aware of what took place before, but I — I realize there are more cases, but I'm just asking, are you witnessing that at present, today?
Liam Kelly
executiveSo, I mean, the United States is the crucial market in this situation. And when you examine the United States and when you examine the period before COVID and the period after COVID and our strongest reference point really is the UroLift business. The states that are — I'm looking at the larger states right now where you hold a great deal of your volume that remain under pre-COVID levels are, Massachusetts, New Jersey, South Carolina; those recovering very strongly and surpassing that are North Carolina, New York and Illinois, just three illustrations. So, what you have is a mixed bag. So, within the United States we have not witnessed those procedures being deferred. But what we have witnessed is in places such as India and indeed in Australia, during the third quarter, we witnessed some procedures being deferred and hospitals delaying them. So, yes, we did observe it in certain geographies. It will be fascinating to see now what we will observe in places such as France and Spain. I think what they will attempt to do is keep patients moving through the hospitals because the greater human tragedy here could be people not receiving procedures, and consequently, experiencing a very poor outcome down the road because they didn't receive those critical procedures that were required because they were frightened of COVID; so, I think, that's a greater human tragedy developing. If we don't keep our hospitals open and keep patients moving through them. And I think the other item that you're noticing, as I mentioned previously, is that patients feel more assured going to the office and the ASC than they do in the hospital and we're noticing particularly with UroLift the office setting, performing rather well relative to the hospital setting getting back to above pre-COVID levels in the office in its entirety within the United States. I hope that responds to your question as precisely as I can.
Dave Turkaly
analystNo, that's fantastic. Thanks. That covers everything on my end. Appreciate it.
Liam Kelly
executiveThanks.
Mike Matson
analystThank you. Regarding UroLift 2, could you share your current view on how this product might affect margins and growth, and when the full switchover to UroLift 2 will happen?
Liam Kelly
executiveSure. The margin remains unchanged. UroLift margins will shift from the mid-70s to high-70s, so expect roughly 4 full percentage points gained in that business; and that business generated around $300 million last year. Rollout will start early in 2021. Adoption should be straightforward for urologists. What we've seen so far from pre-market work has been extremely positive. Physicians genuinely appreciate how the product performs — it's simpler to use, delivers the same grade outcomes, offers the same visibility, everything is the same. I'm very pleased we invested time in adjusting the visibility factor here, since the feedback coming back from urologists is truly favorable. So, once rollout begins in 2021 and we move into 2022, we ought to convert a substantial share of the North American market.
Mike Matson
analystAll right, thank you. Then regarding the OEM segment, you said there's a delayed effect from customers reducing inventory or whatever is going on — do you believe that's mostly finished, or will it carry on through Q4?
Liam Kelly
executiveWell, I believe we'll certainly witness the OEM segment getting better during the fourth quarter. The situation there, Mike, is that clearly we produce goods on behalf of other businesses, brand-name businesses, every one of which you're familiar with, and you likely follow a big share of them. And what we've observed is that when their elective procedures decline, there was a delay before they put orders with our OEM operation, and we anticipated that would occur. This isn't a surprise; we understood the OEM would be hit by COVID one quarter behind the remainder of our operations. We've likewise observed destocking at a number of these major firms as they strengthen their capital position and ensure they're keeping their free cash flow under control. So, some of them have been destocking, and that can only go on for so long. Therefore, I'd anticipate our OEM operation starting to recover in Q4.
Mike Matson
analystExcellent. Thanks very much.
Chris Cooley
analystMorning, and thanks for fielding my question. I'll keep it to just the one for now. That said, Liam or Tom, it would be helpful if you two could give a bit more detail regarding Q4. I don't mean what got left out, such as Z-Medica or the additional selling days — rather, what you baked into that guidance when it comes to hospitals, and especially US hospitals. I'm wondering whether you're building in assumptions around heavier inventory persisting through the close of the calendar year, better throughput when it comes to procedure growth. If that's part of it. I'd just like your take on a few of those outside variables. Many thanks.
Liam Kelly
executiveSure thing, Chris. Thanks for asking. Our approach was to take what we observed in October and essentially carry that forward across the rest of the year. And — we didn't build in any bump in procedures; no assumption of procedures bouncing back, and perhaps that's overly cautious on our part. Even so, we don't expect to return to where we were before COVID during Q4. Our view is still that this happens in early 2021. As for October, the first four weeks of October seemed fairly solid — we were basically level across the opening weeks of October. Once we hit November and December, though, the comparison gets harder. Chris, as you're aware, take UroLift — it was up 54% a year ago, and the whole business did quite well in last year's fourth quarter; so that factored into our thinking. A further lockdown wasn't something we planned for. Our expectation was that COVID would be handled effectively. During October we'd watched cases climb, so that early rise was already part of our thinking when we set out what we anticipate for Q4. Those are the items we put in and the ones we took out. Naturally we took out DTC, we put in the — we took out the billing days, and those contribute roughly 3%, we took out FX; that one ought to work in our favor. We took out — pardon me, I'm drifting back toward what's excluded instead of what's included, Chris, but Z-Medica was also left out, which we're hoping to finalize during Q4.
Chris Cooley
analystThank you, and congratulations.
Liam Kelly
executiveThanks, Chris.
Jake Elguicze
executiveAppreciate it, operator. And thanks as well to all of you who took part in today's call. That wraps up Teleflex Incorporated's third quarter 2020 earnings conference call.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.